Scoop: Resonance Medicine, a protease biotech from David Liu’s lab, shuts down
Resonance Medicine, a two-year-old stealth-stage biotech out of the lab of famed biochemist David Liu, has decided to shut down, Endpoints News has learned.
The biotech, backed by some of the industry’s most prominent investors, decided to shut down because the science was too nascent, a source familiar with the matter told Endpoints on Tuesday. Financing, which has been hard to come by in the current biotech environment, was not a reason, the source noted, asking not to be identified.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
